📊 RLYB Key Takeaways
Is Rallybio Corp (RLYB) a Good Investment?
Rallybio is an early-stage pharmaceutical company with minimal revenue ($212K), severe operating losses (-$8.7M), and significant cash burn (-$8M), indicating no near-term path to profitability despite balance sheet strength. While management has improved losses by 84.5% YoY and maintains a fortress balance sheet with $41.3M cash against minimal debt, the company is essentially pre-revenue with extreme negative margins (-4119% operating margin), raising fundamental concerns about business viability absent transformative clinical or commercial events.
Rallybio remains a development‑stage biotech with de minimis revenue and large operating losses, indicating no durable commercial engine yet. A clean, debt‑free balance sheet and strong liquidity provide near‑term solvency, but ~$31M cash against ~$30M annual operating cash burn implies an ~12‑month runway and likely external financing. YoY net loss improvement appears driven by non‑operating items while core operating losses remain elevated.
Why Buy Rallybio Corp Stock? RLYB Key Strengths
- Fortress balance sheet with $41.3M cash, $4.2M liabilities, zero debt providing 4-5 year cash runway
- Exceptional liquidity position (12.92x current ratio) ensuring short-term solvency
- Revenue growth of 34.9% YoY shows early traction despite negligible base
- Debt-free balance sheet with 14.5x current ratio
- $31.4M cash supporting near-term operations
- YoY revenue growth and improved net loss
RLYB Stock Risks: Rallybio Corp Investment Risks
- Essentially pre-revenue company with only $212K annual revenue and no gross profit data
- Severe negative cash flow (-$8.0M operating cash flow) at unsustainable burn rate
- Extreme operating losses (-$8.7M) and negative margins (-4119% operating margin) with no visible profitability path
- Typical pre-clinical/early-stage biotech with binary outcome risk (success/failure dependent on clinical trials and regulatory approval)
- High operating losses and extreme negative margins
- Short cash runway (~12 months) and dilution risk
- Minimal, potentially volatile revenue and reliance on non-recurring items
Key Metrics to Watch
- Revenue growth trajectory and commercial milestones
- Monthly cash burn rate and runway extension
- Clinical trial progress and pipeline advancement announcements
- Operating cash burn (net cash used in operations)
- Cash and equivalents vs next-12-month funding needs (runway)
Rallybio Corp (RLYB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 12.92x current ratio provides a solid financial cushion.
RLYB Profit Margin, ROE & Profitability Analysis
RLYB vs Healthcare Sector: How Rallybio Corp Compares
How Rallybio Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Rallybio Corp Stock Overvalued? RLYB Valuation Analysis 2026
Based on fundamental analysis, Rallybio Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Rallybio Corp Balance Sheet: RLYB Debt, Cash & Liquidity
RLYB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Rallybio Corp's revenue has grown significantly by 43% over the 5-year period, indicating strong business expansion. The most recent EPS of $-10.61 indicates the company is currently unprofitable.
RLYB Revenue Growth, EPS Growth & YoY Performance
RLYB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $212.0K | -$8.3M | $-1.46 |
| Q3 2025 | $212.0K | -$3.1M | $-0.07 |
| Q2 2025 | $212.0K | -$9.7M | $-0.22 |
| Q1 2025 | N/A | -$9.4M | $-0.21 |
| Q3 2024 | N/A | -$11.5M | $-0.26 |
| Q2 2024 | N/A | -$16.2M | $-0.37 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Rallybio Corp Dividends, Buybacks & Capital Allocation
RLYB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Rallybio Corp (CIK: 0001739410)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RLYB
What is the AI rating for RLYB?
Rallybio Corp (RLYB) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 70% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are RLYB's key strengths?
Claude: Fortress balance sheet with $41.3M cash, $4.2M liabilities, zero debt providing 4-5 year cash runway. Exceptional liquidity position (12.92x current ratio) ensuring short-term solvency. ChatGPT: Debt-free balance sheet with 14.5x current ratio. $31.4M cash supporting near-term operations.
What are the risks of investing in RLYB?
Claude: Essentially pre-revenue company with only $212K annual revenue and no gross profit data. Severe negative cash flow (-$8.0M operating cash flow) at unsustainable burn rate. ChatGPT: High operating losses and extreme negative margins. Short cash runway (~12 months) and dilution risk.
What is RLYB's revenue and growth?
Rallybio Corp reported revenue of $212.0K.
Does RLYB pay dividends?
Rallybio Corp does not currently pay dividends.
Where can I find RLYB SEC filings?
Official SEC filings for Rallybio Corp (CIK: 0001739410) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RLYB's EPS?
Rallybio Corp has a diluted EPS of $-1.46.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RLYB a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Rallybio Corp has a SELL rating with 70% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RLYB stock overvalued or undervalued?
Valuation metrics for RLYB: ROE of -16.5% (sector avg: 15%), net margin of -3,904.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RLYB stock in 2026?
Our dual AI analysis gives Rallybio Corp a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RLYB's free cash flow?
Rallybio Corp's operating cash flow is $-8.0M, with capital expenditures of $0.0. FCF margin is -3,763.2%.
How does RLYB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -3,904.7% (avg: 12%), ROE -16.5% (avg: 15%), current ratio 12.92 (avg: 2).